

## AZD-1222

S

### **Pityriasis rubra pilaris: case report**

A 72-year-old man developed pityriasis rubra pilaris (PRP) following vaccination with AZD-1222 for prophylaxis of COVID-19 infection.

The man presented to the dermatology department of a hospital in India due to erythematous scaly papulosquamous plaques with palmoplantar fissuring and thickening on the face, limbs and trunk for 2 weeks. The soles and palms were affected with diffuse hyperkeratosis, fissuring and erythematous plaques involving the lateral side of the feet. He showed negative Auspitz sign while positive Grattage test. He had no family or personal history of skin disease. His medical history was significant for hypertension being treated by unspecified medications for 8 years. He reported that he had received the first dose of AZD-1222 [Covishield; *dose and route not stated*] 3 weeks prior to the occurrence of skin lesions. Chest X-ray, full blood count, lipid profile, urine microscopy, infectious work-up including COVID-19 test, and liver and kidney function tests were all within normal limits. Based on histological findings post-vaccination PRP was suspected.

The man was successfully treated with unspecified topical corticosteroids and emollients.

Six weeks after the first dose, the man received the second dose of AZD-1222 without recurrence of PRP.